Exploring Cross-Sectional and Longitudinal Associations Among DNA Methylation, Prognostic Proteins, and Symptoms in Patients Prescribed Oral Anticancer Medications for Multiple Myeloma.
5 affiliations
- 1School of Nursing, University of Pittsburgh, Pittsburgh, PA, USA.
- 2School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA.
- 3UPMC Hillman Cancer Center, Pittsburgh, PA, USA.
- 4College of Nursing, The Ohio State University, Columbus, OH, USA.
- 5Center for Research Excellence in Supportive Care (CREST), The Ohio State University James Comprehensive Cancer Center, Columbus, OH, USA.
Abstract
At-home administration of oral anticancer medications (OAM) limits interactions with healthcare providers, therefore limiting opportunities for symptom management, posing threats to medication adherence. Individuals diagnosed with multiple myeloma (MM) experience symptoms from both disease- and treatment-related factors. Proteins Beta-2 Microglobulin (B2M) and Lactate Dehydrogenase (LDH) are routinely used in disease monitoring, yet their associations with symptoms and regulation via DNA methylation (DNAm) in individuals with MM have not been investigated. This study explored relationships among LDH and B2M proteins; DNAm of genes B2M, LDHA, LDHB; and symptoms in patients prescribed OAMs for MM. This was a 6-month, longitudinal, exploratory analysis. Symptoms were assessed using self-reported measures. Protein levels were extracted from medical records. DNAm of B2M, LDHA, and LDHB promoter regions were quantified via pyrosequencing of peripheral blood samples. Linear mixed modeling explored cross-sectional and longitudinal associations. Significant cross-sectional associations were identified between fatigue, LDHA and B2M DNAm, and B2M protein (p < .02); pain and LDHA and B2M DNAm (p < .05); gastrointestinal disturbances and LDHA DNAm and LDH protein (p < .05); shortness of breath and LDHA DNAm (p < .04); and depression and LDH protein (p < .04). Longitudinal interaction effects were significant for B2M DNAm and fatigue (p < .05), LDHA and B2M DNAm and pain (p < .04), and LDH protein and depression (p < .04). Prognostic proteins B2M and LDH and their gene-level DNAm patterns were significantly associated with symptoms in individuals taking OAMs for MM. These preliminary findings support further exploration of multi-omics pathways underlying symptoms to inform symptom identification and management strategies.
Related
- The use of triptans, opioids, and other rescue medications among patients with migraine prescribed calcitonin gene–related peptide inhibitors for migraine prophylaxis
- Primary non-adherence to newly prescribed discharge medications and 30-day adverse outcomes by mental health status: a retrospective cohort study in two tertiary care hospitals in Montréal, Québec, Canada
- Prognostic value of circulating cell-free Epstein-Barr virus DNA CpG methylation in extranodal NK/T cell lymphoma
- MLMP: A Methylation‐Associated lncRNA‐mRNA Prognostic Signature for Endometrial Carcinoma
- Comparative and Histology-Aware Bioinformatic Characterization of FAM171A1 and FAM171A2 in Sarcoma: Expression, Prognostic, and Immune Associations
BibTeX
@article{lustyik2026exploring,
title = {{Exploring Cross-Sectional and Longitudinal Associations Among DNA Methylation, Prognostic Proteins, and Symptoms in Patients Prescribed Oral Anticancer Medications for Multiple Myeloma.}},
author = {Abigail Lustyik and Yvette P Conley and Catherine M Bender and Susan M Sereika and Zhirui Deng and Dianxu Ren and Corrine Bozich and Sarah M Belcher},
journal = {Biological research for nursing},
year = {2026},
month = oct,
doi = {10.1177/10998004261496459},
url = {https://europepmc.org/article/MED/42848710},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Exploring Cross-Sectional and Longitudinal Associations Among DNA Methylation, Prognostic Proteins, and Symptoms in Patients Prescribed Oral Anticancer Medications for Multiple Myeloma.
AU - Abigail Lustyik
AU - Yvette P Conley
AU - Catherine M Bender
AU - Susan M Sereika
AU - Zhirui Deng
AU - Dianxu Ren
AU - Corrine Bozich
AU - Sarah M Belcher
PY - 2026
DA - 2026/10/08
JO - Biological research for nursing
DO - 10.1177/10998004261496459
UR - https://europepmc.org/article/MED/42848710
AB - At-home administration of oral anticancer medications (OAM) limits interactions with healthcare providers, therefore limiting opportunities for symptom management, posing threats to medication adherence. Individuals diagnosed with multiple myeloma (MM) experience symptoms from both disease- and treatment-related factors. Proteins Beta-2 Microglobulin (B2M) and Lactate Dehydrogenase (LDH) are routinely used in disease monitoring, yet their associations with symptoms and regulation via DNA methylation (DNAm) in individuals with MM have not been investigated. This study explored relationships among LDH and B2M proteins; DNAm of genes B2M, LDHA, LDHB; and symptoms in patients prescribed OAMs for MM. This was a 6-month, longitudinal, exploratory analysis. Symptoms were assessed using self-reported measures. Protein levels were extracted from medical records. DNAm of B2M, LDHA, and LDHB promoter regions were quantified via pyrosequencing of peripheral blood samples. Linear mixed modeling explored cross-sectional and longitudinal associations. Significant cross-sectional associations were identified between fatigue, LDHA and B2M DNAm, and B2M protein (p < .02); pain and LDHA and B2M DNAm (p < .05); gastrointestinal disturbances and LDHA DNAm and LDH protein (p < .05); shortness of breath and LDHA DNAm (p < .04); and depression and LDH protein (p < .04). Longitudinal interaction effects were significant for B2M DNAm and fatigue (p < .05), LDHA and B2M DNAm and pain (p < .04), and LDH protein and depression (p < .04). Prognostic proteins B2M and LDH and their gene-level DNAm patterns were significantly associated with symptoms in individuals taking OAMs for MM. These preliminary findings support further exploration of multi-omics pathways underlying symptoms to inform symptom identification and management strategies.
SN - 1099-8004
SN - 1552-4175
ER -